A RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TWO DOSE LEVELS OF ONO-4578 WITH OPDIVO® IN COMBINATION WITH MFOLFOX6 AND BEVACIZUMAB VERSUS STANDARD OF CARE FOR FIRST-LINE TREATMENT OF NON-MSI-H/DMMR, PD-L1 POSITIVE ADVANCED COLORECTAL CANCER
- Registry ID
- ONO-4578-10
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- ONO PHARMACEUTICAL CO LTD
- Start date
- 2025-09-26
- Last update
- 2025-05-27
Conditions
Related clinical trials
- A RANDOMIZED, OPEN LABEL, 3-ARM PHASE 3 STUDY OF PRECEMTABART TOCENTECAN WITH OR WITHOUT BEVACIZUMAB COMPARED TO TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB IN PARTICIPANTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (PROCEADE-CRC-03)
- SAFELY OPTIMIZING BODY WEIGHT WITH MIFOMELATIDE (TCMCB07) IN PATIENTS WITH NEWLY DIAGNOSED COLORECTAL CANCER (CRC) OR PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) UNDERGOING CHEMOTHERAPY
- A PHASE II, OPEN-LABEL, MULTICENTER, MASTER PROTOCOL TO EVALUATE THE
SAFETY AND EFFICACY OF NOVEL STUDY INTERVENTIONS AND COMBINATIONS
IN PARTICIPANTS WITH COLORECTAL CANCER (CANTOR)
- PHASE 3 MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF
SOTORASIB, PANITUMUMAB AND FOLFIRI VERSUS FOLFIRI WITH OR WITHOUT
BEVACIZUMAB-AWWB FOR TREATMENT-NAÏVE SUBJECTS WITH METASTATIC COLORECTAL
CANCER WITH KRAS P.G12C MUTATION (CODEBREAK 301)
- A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY OF AMIVANTAMAB AND MFOLFOX6 OR
FOLFIRI VERSUS CETUXIMAB AND MFOLFOX6 OR FOLFIRI AS FIRST-LINE TREATMENT
IN PARTICIPANTS WITH KRAS/NRAS AND BRAF WILD-TYPE UNRESECTABLE OR
METASTATIC LEFT-SIDED COLORECTAL CANCER
- PHASE I OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, DOSIMETRY, AND PRELIMINARY ACTIVITY OF [177LU]LU-NNS309 IN PATIENTS WITH PANCREATIC, LUNG, BREAST AND COLORECTAL CANCERS
View on source registry